The U.S. Food and Drug Administration announced it has cleared the Simplexa Influenza A H1N1 (2009), a test for the 2009 H1N1 Influenza Virus in patients with signs and symptoms of respiratory infection.
Until this clearance, tests for 2009 H1N1 Influenza were only available through an Emergency Use Authorization (EUA), which allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses of approved or cleared medical products, during the time a declaration of emergency is in effect.
On April 26, 2009, the U.S. Department of Health and Human Services declared a public health emergency due to the 2009 H1N1 Influenza Virus. EUAs for devices will cease to be effective when the public health emergency declaration expires.
“With this clearance, the availability of Simplexa H1N1 test will not be affected when the public health emergency expires,” said Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health.
Using specimens from nasal swabs or nasal aspirates, the Simplexa Influenza A H1N1 (2009) test simultaneously amplifies and detects two regions of the influenza virus genome and an internal control. A positive result indicates that the patient is infected with the 2009 H1N1 influenza virus, but the test does not indicate the stage of infection. A negative result does not preclude influenza virus infection.
The United States experienced its first wave of 2009 H1N1 Influenza Virus in the spring of 2009, followed by a second wave in the fall. The U.S. Centers for Disease Control and Prevention estimates that between 43 million and 88 million cases of 2009 H1N1 occurred between April 2009 and March 13, 2010.
The Simplexa Influenza A H1N1 (2009) test is manufactured by Focus Diagnostics Inc. in Cypress, Calif.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Tuesday, May 25, 2010
FDA Clears First 2009 H1N1 Influenza Virus Test Previously Available Under Emergency Use Authorization
Posted by
Georgia Front Page.com
at
1:49 PM
0
comments
Labels: fayette front page, georgia, georgia front page, H1N1, infection, respiratory, simplexa, test
Sunday, January 17, 2010
FDA Commissioner Addresses Nation's Health Care Professionals on H1N1 Vaccine Safety
FDA Commissioner Margaret A. Hamburg today sent a letter to America’s health care professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on safety monitoring of the 2009 H1N1 vaccines.
“In November, I wrote to thank you for your efforts during the 2009 H1N1 influenza outbreak and to provide information about the development and FDA approval of the H1N1 vaccines,” Hamburg wrote. “I mentioned our continuing robust efforts to monitor the safety of these vaccines and now would like to reassure you that, to date, the safety assessment is very encouraging.
“As a key part of our missions, the FDA, the Centers for Disease Control and Prevention, other agencies across the Department of Health and Human Services, and other parts of the federal government, including the Department of Defense and the Department of Veterans Affairs, have enhanced and expanded our vaccine safety monitoring systems to detect and quickly investigate any unexpected, rare, or serious adverse events. These additional systems enhance our ability to determine whether any adverse events can be attributed to H1N1 influenza vaccines. A detailed description of vaccine safety efforts is available online at www.flu.gov.
“According to the January 8, 2010 update of FDA and CDC vaccine safety monitoring activities, as of December 30, 2009 the total number of doses of H1N1 vaccines distributed was 99.3 million and the vast majority (94%) of adverse events reported to VAERS were classified as "non-serious" (e.g., soreness at the vaccine injection site). Weekly updates on FDA and CDC vaccine safety monitoring activities are available through the VAERS web site http://vaers.hhs.gov/resources/h1n1update#top.”
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter: @GAFrontPage
Posted by
Georgia Front Page.com
at
8:58 AM
0
comments
Labels: adverse, cdc, fayette, fayette front page, fda, georgia, georgia front page, H1N1, influenza, reactions, safety, vaccine
Friday, December 11, 2009
NCPA Commends Pentagon Decision to Cover Pharmacist-Administered Vaccinations
(BUSINESS WIRE)--The Department of Defense today issued an interim final rule designating pharmacies as providers for H1N1, seasonal flu and pneumonia vaccinations under its TRICARE program. The policy change, effective today and expected to be fully implemented later this month, brings the program in line with other insurers that have covered pharmacist-administered vaccinations for years. TRICARE is also seeking comments on additional vaccines that should be covered through community pharmacies.
In response, National Community Pharmacists Association (NCPA) Executive Vice President and CEO Bruce T. Roberts, RPh, issued the following statement:
“NCPA strongly supports the Pentagon’s decision to cover the provision of these critical vaccines at community pharmacies. This is truly a case where everyone wins. The 9.5 million TRICARE-eligible patients gain a convenient new vaccination option. Taxpayers and plan administrators will save money when vaccines are administered at pharmacies instead of costlier doctors’ offices or hospitals. And community pharmacists can welcome millions of new patients through their doors.
“This is a shining example of how community pharmacists can help produce better health outcomes at lower cost. We commend the Defense Department for taking this step, which NCPA has long advocated. In addition, as these benefits are realized, we’re hopeful Pentagon officials will expand the program to cover additional vaccinations.”
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
10:57 AM
0
comments
Labels: fayette, fayette front page, fayetteville, georgia, georgia front page, H1N1, interim, peachtree city, pharmacies, pneumonia, policy, providers, rules, seasonal, tricare, tyrone, vaccines
Sunday, December 6, 2009
Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease
/PRNewswire/ -- Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans.(1) Research presented today at the 51st Annual Meeting of the American Society of Hematology highlights intriguing studies on the acute danger that the H1N1 pandemic presents for children with this blood disorder, evaluations of both new and standard treatments for common complications of sickle cell disease, and an expansion of the current understanding of hemoglobin expression in red blood cells that may lead to new treatments.
"Treatment for sickle cell disease consists primarily of life-long supportive care, with the only cure being bone marrow transplantation -- a risky procedure that is not readily available for most patients," said Alexis Thompson, MD, PhD, moderator of the press conference and Hematology Section Head at the Children's Memorial Hospital and Associate Professor of Pediatrics, at Northwestern University Feinberg School of Medicine, Chicago. "Therefore, research in this area is particularly important to help ensure that improved therapies continue to be developed and that patients with sickle cell disease have access to the best possible care."
NOTES:
(1) National Heart, Lung, and Blood Institute. Facts About Sickle Cell Anemia. Available at: http://www.nhlbi.nih.gov/health/public/blood/sickle/sca_fact.pdf.
Control of Hemoglobin Switching by BCL11A [Abstract #5]
As infants develop in the womb, the gamma-globin gene produces a fetal form of hemoglobin, the protein inside red blood cells that carries oxygen. Shortly after birth, a switch to beta-globin gene expression normally occurs, which leads to the production of adult hemoglobin. Both fetal and adult hemoglobin function similarly, though fetal hemoglobin has a greater affinity for binding with oxygen.
Patients with sickle cell disease have a defective form of adult hemoglobin that causes their red blood cells to become deformed and sickle shaped. As a result, the cells are unable to efficiently carry oxygen to the body's tissues and often stick together and jam vessels, causing blood flow obstruction and episodes of severe pain. If a patient with sickle cell could continue production of the fetal hemoglobin and produce less of their defective adult sickle hemoglobin, many of their complications could possibly be reduced or eliminated. A team of researchers from Harvard Medical School in Boston studied the therapeutic possibility of turning the genetic "switch" back on for the production of fetal hemoglobin to replace the defective adult hemoglobin and alleviate these devastating symptoms.
In previous studies, a gene called BCL11A was found to be involved in blocking the expression of fetal hemoglobin in adults. To test these findings in vivo and investigate the role of BCL11A in hemoglobin regulation at different developmental stages, the researchers performed genetic tests in both embryonic and adult mice that were genetically engineered to carry a complete human beta-globin gene cluster capable of producing adult hemoglobin.
In the embryonic mice, inactivation of the BCL11A gene led to a robust expression of gamma-globin (the fetal form of hemoglobin) during late gestation: more than 90 percent of the globin produced was of this type. Tissue-specific deletion of the BCL11A gene in the adult mice (8-10 weeks old) resulted in an increase of more than 1,000-fold in gamma-globin gene expression in the bone marrow erythroblasts (the precursors to red blood cells) of the experimental mice in comparison to control mice. This increase in the gamma-globin expression after inactivation of BCL11A was rapid and persisted during the course of the experiments (up until the mice were 25 weeks old).
"Currently, there are only a limited number of therapies available for patients with sickle cell disease and thalassemia, another disorder involving abnormal hemoglobin," said senior study author Stuart H. Orkin, MD, David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Children's Hospital Boston, and Harvard Medical School in Boston. "This research opens up a new avenue for treatment, a way to genetically activate healthy fetal hemoglobin in the red blood cells of patients with these lifelong blood disorders."
Hydroxyurea in Children With Sickle Cell Disease: Practice Patterns and Barriers to Utilization
[Abstract #242]
Sickle cell disease is often marked by episodes of severe and incapacitating pain called vaso-occlusive painful events, which can sometimes require hospitalization. Hydroxyurea, an oral drug that is most commonly taken once daily, was approved by the U.S. Food and Drug Administration for use in sickle cell disease patients in 1998. While hydroxyurea remains the standard of care for reducing these painful events in adults, little is known about its practice patterns in children. Researchers from the Medical College of Wisconsin and Children's Research Institute of the Children's Hospital of Wisconsin in Milwaukee investigated the patterns and barriers to hydroxyurea use in children with sickle cell disease.
In this study, researchers surveyed members of the American Society of Pediatric Hematology/Oncology about their practices and patients. Of the 1,128 surveys disseminated, 31 percent (350 surveys) were returned.
To standardize and increase the quality of care for both adults and children with sickle cell disease, the National Heart, Lung, and Blood Institute (NHLBI) provides clinical practice guidelines for the management of this blood disorder. Most of the survey respondents had heard of (87 percent) and read (78 percent) these guidelines, and provider utilization of hydroxyurea correlated with awareness of the NHLBI recommendations.
The survey found that only 8 percent of providers had half or most (50 to 90 percent) of their pediatric patients with sickle cell disease on hydroxyurea. Another 54 percent of providers had 10 to 30 percent of pediatric patients on the therapy, and 10 percent of providers had fewer than 10 percent of pediatric patients on hydroxyurea. Although a majority of providers (90 percent) felt that hydroxyurea was effective or very effective for the prevention of pain, some still did not prescribe the drug to eligible children because of apprehension about future reproductive issues (birth defects and infertility in males), despite insufficient evidence to support this concern. Low patient compliance was cited by 86 percent of providers as another reason they did not prescribe hydroxyurea. Providers reported that children and their families refused hydroxyurea because of a fear of cancer or other possible side effects, concerns that the drug would not work, compliance with required laboratory monitoring, or because they simply did not want to take medication.
The study also found that many providers prescribed hydroxyurea for reasons other than that for which it was intended, despite insufficient evidence of its efficacy for other complications of the disease.
"Our survey suggests a substantial variation in hydroxyurea utilization in children with sickle cell disease with barriers to its use found on the part of both providers and patients," said lead study author Amanda M. Brandow, DO, MS, Assistant Professor of Pediatrics at the Medical College of Wisconsin and the Children's Research Institute of the Children's Hospital of Wisconsin in Milwaukee. "To alleviate this problem, future research in the following areas may help: continued funding of studies to determine the efficacy of hydroxyurea for complications other than pain, evaluating unconfirmed toxicities of the drug that influence practice, exploring how access to care contributes to noncompliance, and research on methods to promote patient adherence to recommended medical care."
Dr. Brandow will present this study during an oral session on Monday, December 7, at 7:15 a.m. in Room 388-390.
Increased Severity of Pandemic H1N1 Influenza in Children and Young Adults With Sickle Cell Disease [Abstract #264]
Patients with sickle cell disease are more susceptible to infection than the general population. In particular, influenza, a viral disease that affects the respiratory system, is more than 50 times more frequent in children with sickle cell disease than in the general population, according to research conducted by John J. Strouse, MD, PhD, the lead author on this study, and colleagues. As H1N1 influenza, which began circulating in the United States in April 2009, has been reported to cause more severe illness in children and young adults than seasonal flu, researchers from The Johns Hopkins University School of Medicine in Baltimore sought to compare the clinical characteristics and complications associated with these infections in sickle cell disease patients under the age of 21 through a prospective analysis of patient discharge and billing records from September 1993 through July 2009.
During the study period, 99 patients who were seen at The Johns Hopkins Hospital in Baltimore were identified as having both sickle cell disease and influenza (89 with seasonal influenza and 10 with H1N1 influenza). Clinical symptoms, such as fever, cough, and runny nose, were similar between the two groups, although those with H1N1 influenza were at an estimated three-fold increased risk for life-threatening complications, such as acute chest syndrome (a severe lung illness), and nine times more likely to require intensive care, such as ventilator support.
"Our findings underscore that receiving a vaccination against H1N1 influenza, in addition to seasonal influenza, is extremely important for the health and safety of children and young adults with sickle cell disease," said lead author John J. Strouse, MD, PhD, Assistant Professor of Pediatrics and Medicine at The Johns Hopkins University School of Medicine in Baltimore.
Dr. Strouse will present this study in an oral session on Monday, December 7, at 8:15 a.m. in Room 220-222.
Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients With Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial [Abstract #571]
As patients with sickle cell disease have a high rate of hemolysis (red blood cell destruction), excessive amounts of hemoglobin are released into the blood stream that react with and destroy nitric oxide, a critical regulator that dilates blood vessels and inhibits clotting. This can lead to pulmonary hypertension, or abnormally high blood pressure in the arteries of lungs that also affects the heart. Approximately 10 to 30 percent of patients with sickle cell disease are suspected to have this life-threatening condition.
While the oral drug sildenafil (known as Revatio®) is approved to treat pulmonary arterial hypertension, it is unknown whether it is a safe and effective treatment for pulmonary hypertension in those with sickle cell disease. Therefore, a 16-week, double-blind clinical trial, known as the Walk-PHaSST study (treatment of Pulmonary Hypertension and Sickle cell disease with Sildenafil Therapy) was conducted in 10 medical centers in the United States and United Kingdom to test this application in adults and children over 12 years of age with sickle cell disease.
Before starting treatment, potential study participants were given baseline tests, including a Doppler echocardiogram and a six-minute walk test to measure heart and lung function. Seventy-four patients who had a tricuspid regurgitant jet velocity (TRV) of greater than or equal to 2.7 m/s (a sign of suspected high pulmonary blood pressure) and a six-minute walking distance of only 150-500 meters (reflecting decreased exercise capacity) were included in the study. The researchers then randomly assigned the study participants into two groups of 37 patients each. Half of the patients were treated with sildenafil at escalating doses from 20, 40, and 80 mg three times per day, and the other half received a placebo three times per day. In previous studies of patients with primary pulmonary hypertension, the highest dose of sildenafil (80 mg) had the greatest effect on blood circulation; however, to monitor for possible adverse effects associated with escalating doses, the sildenafil doses in this study were increased slowly, with dose increases made every four weeks.
The study was prematurely stopped when a significant number of the patients in the sildenafil treatment arm (46 percent) began experiencing serious side effects (primarily sickle cell pain crises requiring hospitalization), compared with only 22 percent of those in the placebo arm. Headache and blurred vision, which were expected side effects of sildenafil, were also experienced. The patients in the sildenafil group had more headaches (27 percent versus 14 percent) and more blurred vision (11 percent versus 3 percent) than the placebo group.
Prior to stopping the study, 33 patients had completed the 16-week assessment and were found to have no change in TRV value or in the walking distance test. On pain questionnaires, patients on the sildenafil treatment also reported worsening pain during walking and less enjoyment of life when compared to the patients on placebo.
"Although sildenafil is approved by the U.S. Food and Drug Administration and by the European Medicines Agency for patients with pulmonary arterial hypertension, the Walk-PHaSST study was prematurely stopped for safety concerns. However, these preliminary data should not be interpreted as implying that sildenafil may not be efficacious and safe in select sickle cell patients with documented pulmonary hypertension who are at low risk for vaso-occlusive events," said lead study author Mark Gladwin, MD, Chief of the Division of Pulmonary, Allergy, and Critical Care Medicine and Director of the Vascular Medicine Institute at the University of Pittsburgh Medical Center. "Further investigations are critically needed to find a safe and effective treatment for this patient population at high risk for death from this debilitating condition."
Dr. Gladwin will present this study in an oral session on Monday, December 7, at 2:45 p.m. in Room 220-222.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:19 PM
0
comments
Labels: ASH, fayette, fayette front page, genetic, georgia, georgia front page, H1N1, health, hematology, sickle cell, studies, treatment
Monday, November 16, 2009
FDA Approves Additional Vaccine for 2009 H1N1 Influenza Virus
The U.S. Food and Drug Administration announced that it has approved a fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC.
As with the four previous H1N1 influenza vaccines licensed by the FDA on Sept.15, 2009, ID Biomedical Corporation will manufacture its H1N1 vaccine using the established, licensed egg-based manufacturing process used for producing seasonal flu vaccine.
Potential side effects of this H1N1 vaccine are expected to be similar to those of the seasonal and H1N1 flu vaccines. The most common side effect is soreness at the injection site. Others may include mild fever, body aches and fatigue for a few days after the inoculation.
As with any medical product, unexpected or rare serious adverse events may occur. The FDA is collaborating with other government agencies to enhance adverse event safety monitoring during and after the H1N1 2009 vaccination program.
ID Biomedical’s H1N1 monovalent vaccine will be produced in multi-dose vials, in a formulation that contains thimerosal.
As with any medical product, unexpected or rare serious adverse events may occur. FDA is collaborating with the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention, and other government agencies to enhance the capacity for adverse event safety monitoring during and after the 2009 H1N1 vaccination program.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
3:24 PM
0
comments
Labels: approval, fayette, fayette front page, fda, flu vaccine, georgia, georgia front page, H1N1, vaccine
FDA Expands Use of CSL Limited’s Seasonal and H1N1 Vaccines to Infants and Children
The U.S. Food and Drug Administration has approved the use of the CSL Limited’s seasonal and 2009 H1N1 influenza vaccines to include children ages 6 months and older. These vaccine were previously approved for use in adults, ages 18 years and older
“Because children are among those most vulnerable to the 2009 H1N1 virus, having a broader range of vaccines available for use in children is an important step in responding to the H1N1 outbreak,” said Margaret A. Hamburg, M.D., commissioner of food and drugs.
The company’s 2009 H1N1 vaccine is manufactured and tested using the same well-established licensing processes that have been in place for many years for the company’s seasonal flu vaccine.
The approval was based on a study of the company’s seasonal flu vaccine in children, showing both the vaccine's safety and its ability to induce antibodies expected to protect against influenza. These findings supported approval under FDA's accelerated approval regulations, which help safe and effective medical products for serious or life-threatening diseases to become available sooner to the public.
Common adverse events experienced by children after administration of seasonal and H1N1 vaccines typically include pain, redness and swelling at the injection site as well as, in some cases, irritability, loss of appetite and drowsiness.
As with any medical product, unexpected or rare serious adverse events may occur. FDA is collaborating with the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention, and other government agencies to enhance the capacity for adverse event safety monitoring during and after the 2009 H1N1 vaccination program.
Because CSL’s seasonal and H1N1 monovalent vaccines contain a small amount of egg protein, they should not be administered to anyone allergic to eggs or egg products.
The vaccines will be available both in single-dose, preservative-free, pre-filled syringes and in multi-dose vials that contain thimerosal, a mercury derivative, as a preservative.
Both vaccines are manufactured by CSL Ltd. of Australia.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
12:50 PM
0
comments
Labels: approval, children, fayette, fayette front page, fda, flu, flu vaccine, georgia, georgia front page, H1N1, seasonal, vaccine
Thursday, November 12, 2009
FDA Expands Approved Use of H1N1 Vaccines to Include Infants and Children
The U.S. Food and Drug Administration has approved the use of the CSL Limited’s 2009 H1N1 influenza vaccine to include children ages 6 months and older. This vaccine was previously approved only for use in adults, ages 18 years and older.
“Because children are among those most vulnerable to the 2009 H1N1 virus, having a broader range of children’s vaccines available is an important step in responding to the H1N1 outbreak,” said Margaret A. Hamburg, M.D., commissioner of food and drugs.
The company’s 2009 H1N1 vaccine is manufactured and tested using the same well-established licensing processes that have been in place for many years for the company’s seasonal flu vaccine. The expanded approval also covers the company’s seasonal flu vaccine.
The approval was based on a study of the company’s seasonal flu vaccine in children showing the vaccine's safety and efficacy in inducing antibodies to protect against influenza. These efficacy findings supported approval under FDA's accelerated approval regulation, which helps safe and effective medical products for serious or life-threatening diseases to become available sooner to the public.
Common adverse events experienced by children after administration of seasonal and H1N1 vaccines typically include pain, redness and swelling at the injection site as well as, in some cases, irritability, loss of appetite and drowsiness.
As with any medical product, unexpected or rare serious adverse events may occur. FDA is collaborating with the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention, and other government agencies to enhance the capacity for adverse event safety monitoring during and after the 2009 H1N1 vaccination program.
Because CSL’s seasonal and H1N1 monovalent vaccines contain a small amount of egg protein, they should not be administered to anyone allergic to eggs or egg products.
The vaccines will be available in single-dose, preservative-free, pre-filled syringes and in multi-dose vials that contain thimerosal, a mercury derivative, as a preservative.
Both vaccines are manufactured by CSL Ltd. of Australia.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:32 PM
0
comments
Labels: approval, children, fayette, fayette front page, fda, georgia, georgia front page, H1N1, influenza, vaccinate
Friday, November 6, 2009
HHS Orders Intravenous Antiviral Flu Medication to Help Patients Hospitalized with 2009 H1N1
The U.S. Department of Health and Human Services (HHS) today (November 5) announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients.
Patients hospitalized with 2009 H1N1 influenza are evaluated to determine if antiviral drugs will be useful; some patients are not able to take the drugs that are currently available as pills or liquid and may benefit from intravenous antiviral medications.
To help meet the potential need for IV medications to combat the H1N1 virus, HHS ordered 10,000 treatment courses each from BioCryst, Roche and GlaxoSmithKline, totaling $31.5 million. The contracts allow HHS to place additional orders of up to 30,000 treatment courses with each manufacturer over two years. Roche manufactures Tamiflu; GlaxoSmithKline, Relenza, and BioCryst manufactures Peramivir.
Because there are no Food and Drug Administration (FDA)-approved antiviral medications that can be administered intravenously to treat influenza, the FDA issued an emergency use authorization on Oct. 23 to allow use of intravenous peramivir, an investigational antiviral drug in the class of drugs known as neuraminidase inhibitors.
The HHS orders for intravenous oseltamivir (Tamiflu) and intravenous zanamivir (Relenza), also neuraminidase inhibitors, are predicated on FDA emergency use authorization for these medications.
FDA has not issued emergency use authorization authorizing the use of intravenous Tamiflu or Relenza. Orders for Tamiflu and Relenza are based on anticipated need of emergency use authorizations for additional IV drugs in the future. Tamiflu and Relenza) are FDA-approved in the form of pills or liquid, and studies are ongoing into the use of these two drugs intravenously for hospitalized H1N1 flu patients.
The emergency use authorization for IV peramivir allowed doctors to prescribe the drug to treat certain adults and children hospitalized with confirmed or suspected 2009 H1N1 infections. Specifically, IV peramivir is authorized only for hospitalized adult and pediatric patients for whom therapy with an IV drug is clinically appropriate.
To authorize emergency use of any product, the FDA commissioner must determine that in an emergency, based on the totality of scientific evidence available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing the serious or life threatening disease or condition; that the known and potential benefits of the product outweigh the known and potential risks of the product in the emergency situation, and that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such serious or life threatening disease or condition.
The Biomedical Advanced Research and Development Authority (BARDA) within the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) will manage the contracts. BARDA supported the advanced development of IV peramivir beginning in 2007 as part of a larger HHS initiative to develop promising new influenza medications and vaccines.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
9:32 AM
0
comments
Labels: antiviral, authoriztion, drugs, fayette, fayette front page, fayetteville, fda, georgia, georgia front page, H1N1, hospitalized, influenze, IV, patients, peachtree city, relenza, tamiflu, treatment
Friday, October 23, 2009
FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings
The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.
Specifically, IV peramivir is authorized only for hospitalized adult and pediatric patients for whom therapy with an IV drug is clinically appropriate, based on one or more of the following reasons:
1. the patient is not responding to either oral or inhaled antiviral therapy, or
2. when drug delivery by a route other than an intravenous route -- e.g., enteral (absorbed by the intestines) or inhaled -- is not expected to be dependable or feasible;
3. for adults only, when the clinician judges IV therapy is appropriate due to other circumstances.
The FDA has reviewed the available scientific data and has concluded that the criteria for authorizing the emergency use of IV peramivir have been met.
There are no FDA-approved intravenously administered antivirals for the treatment of influenza. Peramivir is the only intravenously administered influenza treatment currently authorized for use under EUA for 2009 H1N1 infections.
The EUA authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses of approved or cleared medical products following a determination and declaration of emergency, provided certain criteria are met. The authorization will end when the declaration of emergency is terminated or the authorization is revoked by the agency.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
9:04 PM
0
comments
Labels: atlanta, authorize, emergency, fayette front page, fda, georgia, georgia front page, H1N1, hospital, peramivir
Friday, October 9, 2009
H1N1 Vaccine Priority Groups Expanded
District 4 Public Health has received the first shipment of H1N1 vaccine at county health departments. Georgia's initial shipment of 54,800 doses of H1N1 vaccine was earmarked for young children. However, vaccine administration is now open on a first come, first serve basis to:
· Children and young adults ages 2-24 years
· Healthcare providers
· Emergency Responders
· Contacts or caregivers of infants less than 6 months of age
2009 H1N1 vaccine is CURRENTLY available at all health departments in District 4 in the form of nasal-spray flu vaccine, also known as LAIV for live attenuated influenza vaccine. No appointment is needed and vaccine will be given on a first come, first serve basis. H1N1 vaccine is being provided free of charge by Public Health, although administration fees may be charged to insurance, Medicaid or Medicare.
Additional nasal spray vaccine and a shipment of H1N1 injectible vaccine is expected soon but no delivery date has been given at this time.2009 H1N1 nasal spray is approved for people from 2 through 49 years of age with the following exceptions:
· pregnant women,
· anyone with a weakened immune system,
· anyone with a long-term health problem such as - heart disease - kidney or liver disease - lung disease - metabolic disease such as diabetes - asthma - anemia and other blood disorders
· children younger than 5 years with asthma or one or moreepisodes of wheezing during the past year,· anyone with certain muscle or nerve disorders (such as cerebral palsy) that can lead to breathing or swallowing problems,· anyone in close contact with a person with a severely weakened immune system (requiring care in a protected environment, such as a bone marrow transplant unit),
· children or adolescents on long-term aspirin treatment.
“Our first shipment of H1N1 shots will be given to pregnant women and people in the current priority group who cannot receive nasal spray flu vaccine,” said Dr. Michael Brackett District 4 medical director.
District 4 Public Health has activated a regional public health hotline (888.899.9788) that provides callers with H1N1 vaccine availability information. People can also get information on H1N1 vaccine availability at www.district4health.org. Health departments will be closed on Monday, October 12, 2009 in observance of the Columbus Day holiday but will reopen Tuesday at 8:00 a.m. For more information on seasonal and H1N1 flu visit www.flu.gov.
---
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---
Posted by
Georgia Front Page.com
at
4:00 PM
0
comments
Labels: county, flu, georgia front page, H1N1, health, swine flu, vaccine
Tuesday, September 29, 2009
MAG Promoting Both Seasonal Flu and H1N1 Vaccinations
The Medical Association of Georgia (MAG) is reminding Georgians to get their annual flu vaccination, and the leading voice for physicians in the state also says that patients should get vaccinated for the H1N1 flu as soon as the vaccine is available.
“The seasonal flu vaccine is different from the H1N1 swine flu vaccine,” MAG president M. Todd Williamson, M.D., explains. “We’re talking about different viruses, so you need to get both vaccines to be fully protected this year.”
Dr. Williamson is encouraging patients to consult with their primary care physician to determine specifically when they should get vaccinated based on their age and health profile, as well as the availability of the vaccines. He says the seasonal flu and H1N1 vaccines can be administered on the same day, though he adds that it will still be several weeks before the H1N1 vaccine is available. He also points out that the H1N1 vaccination might require two injections for children nine and younger – pending the outcome of some clinical trials that are underway.
Dr. Williamson says the priority groups for the H1N1 vaccination include people six months to 24 years; people who live with or care for children younger than six months; pregnant women; health care and emergency medical services personnel; and people 25 to 64 who have health conditions associated with higher risk of medical complications from influenza.
Dr. Williamson explains that influenza is a contagious respiratory illness that is caused by influenza viruses. Most people who get the flu will recover in a matter of days, but he stresses that more serious complications like pneumonia can occur. Dr. Williamson says that the flu can include a variety of symptoms, including a high fever, headache, extreme tiredness, dry cough, sore throat, muscle aches, and stomach symptoms such as nausea, vomiting, and diarrhea.
Dr. Williamson says the flu shot and the nasal-spray vaccine are effective preventative measures when it comes to the seasonal flu.
In terms of advice, Dr. Williamson says, “The best ways to protect yourself from the flu are to wash your hands on a regular basis and to get your flu vaccinations from your primary care physician as part of your overall health maintenance program.”
Go to www.flu.gov for additional information on the flu and flu vaccines. Go to www.mag.org for additional information on MAG.
---
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---
Posted by
Georgia Front Page.com
at
10:41 AM
0
comments
Labels: association, county, fayette, fayette front page, fayetteville, flu, georgia, georgia front page, H1N1, MAG, medical, peachtree city, swine, tyrone, vaccinatin
Tuesday, September 15, 2009
FDA Approves Vaccines for 2009 H1N1 Influenza Virus
The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.
“Today's approval is good news for our nation's response to the 2009 H1N1 influenza virus,” said Commissioner of Food and Drugs Margaret A. Hamburg, M.D. “This vaccine will help protect individuals from serious illness and death from influenza.”
The vaccines are made by CSL Limited, MedImmune LLC, Novartis Vaccines and Diagnostics Limited, and sanofi pasteur Inc. All four firms manufacture the H1N1 vaccines using the same processes, which have a long record of producing safe seasonal influenza vaccines.
”The H1N1 vaccines approved today undergo the same rigorous FDA manufacturing oversight, product quality testing and lot release procedures that apply to seasonal influenza vaccines,” said Jesse Goodman, M.D., FDA acting chief scientist.
Based on preliminary data from adults participating in multiple clinical studies, the 2009 H1N1 vaccines induce a robust immune response in most healthy adults eight to 10 days after a single dose, as occurs with the seasonal influenza vaccine.
Clinical studies under way will provide additional information about the optimal dose in children. The recommendations for dosing will be updated if indicated by findings from those studies. The findings are expected in the near future.
As with the seasonal influenza vaccines, the 2009 H1N1 vaccines are being produced in formulations that contain thimerosal, a mercury-containing preservative, and in formulations that do not contain thimerosal.
People with severe or life-threatening allergies to chicken eggs, or to any other substance in the vaccine, should not be vaccinated.
In the ongoing clinical studies, the vaccines have been well tolerated. Potential side effects of the H1N1 vaccines are expected to be similar to those of seasonal flu vaccines.
For the injected vaccine, the most common side effect is soreness at the injection site. Other side effects may include mild fever, body aches, and fatigue for a few days after the inoculation. For the nasal spray vaccine, the most common side effects include runny nose or nasal congestion for all ages, sore throats in adults, and -- in children 2 to 6 years old -- fever.
As with any medical product, unexpected or rare serious adverse events may occur. The FDA is working closely with governmental and nongovernmental organizations to enhance the capacity for adverse event monitoring, information sharing and analysis during and after the 2009 H1N1 vaccination program. In the U.S. Department of Health and Human Services, these agencies include the Centers for Disease Control and Prevention.
Vaccines against three seasonal virus strains are already available and should be used (see information on the seasonal flu). However, they do not protect against the 2009 H1N1 virus (see information on H1N1 flu).
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
3:25 PM
0
comments
Labels: approval, atlanta, fayette front page, fda, georgia, georgia front page, H1N1, influenza, vaccines
Friday, September 11, 2009
Statement by Dr. Anthony Fauci, NIH Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults
Statement by Dr. Anthony Fauci
Director, National Institute of Allergy and Infections Diseases, NIH
Regarding Early Results from Clinical Trials of 2009 H1N1 Influenza
Vaccines in Healthy Adults
We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. We expect additional companies to announce their preliminary trial results shortly. The early data from these trials
indicate that 2009 H1N1 influenza vaccines are well tolerated and induce a strong immune response in most healthy adults when administered in a single unadjuvanted 15-microgram dose. We congratulate the companies on these trials, which are an important part of the ongoing worldwide effort to develop vaccines to protect the public from 2009 H1N1 influenza.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, also is conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited. The NIAID trials are testing two different dosages (15 micrograms versus 30 micrograms) and evaluating the immune response to one and two doses of these vaccines. More than 2,800 people are participating in ongoing NIAID trials of these vaccines.
We are pleased to note that preliminary analyses of early data from the NIAID trials align with the recently announced findings and those to be announced imminently by other companies in that both vaccines studied induced what is likely to be a protective immune response in most adults following a single dose in the same amount (15 micrograms) used in seasonal flu vaccines. Specifically, in blood samples obtained 8 to 10 days after vaccination:
* Among healthy adults who received a single 15-microgram dose of
the Sanofi Pasteur vaccine, a robust immune response was measured in 96
percent of adults aged 18 to 64 and in 56 percent of adults aged 65 and
older.
* Similarly, among healthy adults who received a single
15-microgram dose of the CSL Limited vaccine, a robust immune response
was measured in 80 percent of adults aged 18 to 64 and in 60 percent of
adults aged 65 and older.
Additional data from the NIAID trials are forthcoming. However, on the basis of these strong early data, our results are consonant with other reports that a single 15-microgram dose of unadjuvanted 2009 H1N1 influenza vaccine is well tolerated and induces a robust immune response in healthy adults between the ages of 18 and 64. For adults aged 65 and over, the immune response to 2009 H1N1 influenza vaccine is somewhat less robust, as is the case with seasonal influenza vaccines.
We note that the slight discrepancies seen in our trials between the Sanofi Pasteur and CSL Limited vaccines may be due to technical differences in the preliminary measurement of the amounts of antigen in the doses used in the clinical trial lots and the relatively limited numbers of samples studied to date, as well as the fact that our data are drawn from a very early time point after immunization.
NIAID will continue to provide timely updates on these trials as well as those in children and in pregnant women, which began later.
Information from the NIAID studies will help inform the development of recommendations for immunization schedules, including the optimal dosage and number of doses for different age groups.
NIAID is conducting these clinical trials through its longstanding vaccine clinical trials infrastructure: the Vaccine and Treatment Evaluation Units, a network of medical centers that offers rapid response capability to test vaccines for emerging public health concerns. Detailed information is available from the NIAID Web site (www.niaid.nih.gov) and from http://ClinicalTrials.gov.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
3:02 PM
0
comments
Labels: atlanta, clinical trials, fayette front page, flu vaccine, georgia, georgia front page, H1N1, H1N1 vaccine, influenza, NIH, report, results, vaccine
Tuesday, September 1, 2009
Three Federal Agencies Join with Sesame Workshop to Launch National PSA Campaign Stressing Healthy Habits to Prevent H1N1 Flu Infection
The Department of Health and Human Services, the Department of Homeland Security, the Department of Education and Sesame Workshop, the nonprofit educational organization behind Sesame Street, have teamed up to launch a new, national public service advertising campaign designed to encourage American children and families to practice healthy habits and to take steps to prevent the spread of the 2009 H1N1 flu virus. The PSAs featured in this campaign can be viewed on www.flu.gov.
During the spring, the Sesame Workshop produced four different versions of a television PSAsfeaturing Sesame Street's Elmo and Gordon explaining the importance of practicing healthy habits such as washing your hands, sneezing into the bend of your arm, and avoiding contact with your eyes, nose and mouth. They have now been reformatted to promote www.flu.gov, the federal government's one-stop website for all the latest information on the new H1N1 virus and the seasonal flu. The PSAs will be distributed nationwide and will be supported in airtime donated by television stations.
"We are thrilled to partner with Elmo, Gordon, and Sesame Workshop again to emphasize the steps kids and their parents can take to stay happy and healthy this school year," said Secretary Sebelius. "Younger children and their parents are some of the people most at risk from the new H1N1 flu virus and with schools starting back up again and the weather starting to get colder, we need to do everything we can to get these important messages about how to prevent the spread of the flu out there.
"The first day of National Preparedness Month is a great reminder that personal preparedness starts at home and these PSAs promote simple things we can all do to stay healthy and safe," said DHS Secretary Janet Napolitano."
"We want to keep our children safe, healthy, and learning. By practicing prevention, close monitoring and common sense, we can help prevent the spread of H1N1 and seasonal flu among children and young people this year" Secretary Duncan said. "Having Elmo and our friends at Seasame Street help get that message out there will be a tremendous help."
"Sesame Street's Elmo can be a powerful messenger in delivering simple, yet compelling messages that teach a child to wash their hands and cover their mouth this flu season," said Gary E. Knell, President and CEO, Sesame Workshop. "These vital prevention messages must be part of a larger flu strategy and Sesame Workshop is proud to be partnering with the Department of Health and Human Services to ensure that parents and their young children receive the information they need to stay healthy."
In late May, Sesame Workshop first partnered with the Department of Health and Human Services on a new PSA campaign focused on the importance of providing parents, teachers and children with accurate information about how to practice healthy habits, highlighting proper hand washing and simple everyday actions that lead to staying healthy and keeping germs away. The PSAs are an extension of Sesame's Healthy Habits for Life initiative, which helps young children and their caregivers establish an early foundation of healthy habits.
On a global scale, Sesame Workshop was the first nonprofit to respond to the flu outbreak in Mexico, with the immediate creation of four PSAs featuring the beloved Muppets of Plaza Sésamo and several Mexican celebrities who donated their time to the cause. The flu prevention messaging has reached millions of children and their families both in Mexico and the United States.
The PSAs are part of an initiative to provide practical steps recommended by the Centers for Disease Control and Prevention (CDC) to help prevent the spread of the flu virus and other infectious disease, including:
* Avoid close contact with people who are sick.
* Keep your distance from others if you are sick.
* When possible, stay home from work, school, and errands when you are sick, and don't send your children to childcare or school if they are sick.
* Cover your mouth and nose when coughing or sneezing.
* Wash your hands often with soap and water, especially after coughing and sneezing.
* Avoid touching your eyes, nose and mouth.
The Department of Health and Human Services will be distributing the PSAs via satellite to television stations nationwide later this afternoon. Feed information will be sent out later today.
For more information on how to take steps to prevent the flu, visit www.flu.gov.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Posted by
Georgia Front Page.com
at
8:39 AM
0
comments
Labels: atlanta, campaign, education, fayette front page, georgia, georgia front page, H1N1, habits, healthy, PSA, sesame street
Wednesday, August 19, 2009
Federal Guidelines Encourage Employers to Plan Now for Upcoming Influenza Season
Recommendations Range from Encouraging Hand Washing to Allowing Some Employees to Stay Home
Department of Commerce (DOC) Secretary Gary Locke, Department of Health and Human Services (HHS) Secretary Kathleen Sebelius, and Homeland Security (DHS) Secretary Janet Napolitano today announced new guidance for businesses to plan for and respond to the upcoming flu season.
The guidance, released by the Centers for Disease Control and Prevention (CDC), is designed to help employers prepare now for the impact of seasonal and 2009 H1N1 influenza could have this fall and winter on their employers and operations.
Employers' plans should address such points as encouraging employees with flu-like symptoms or illness to stay home, operating with reduced staffing, and possibly having employees who are at higher risk of serious medical complications from infection work from home, according
to the CDC guidance.
It is not known whether the 2009 H1N1 influenza virus will cause more illness or more severe illness in the coming months, but the CDC recommends that everyone be prepared for influenza. Because seasonal and 2009 H1N1 influenza pose serious health threats, employers should
work with employees to develop and implement plans that can reduce the spread of flu, and to encourage seasonal flu vaccination as well as H1N1 vaccination when that vaccine becomes available.
Secretary Locke suggested businesses set the right tone in the workplace. That means implementing common sense measures to reduce the risk of spreading the flu and encouraging workers who are sick to stay home.
"The President has mobilized the federal government to get America prepared," DOC Secretary Locke said. "But government can't do it alone. For this effort to be successful, we need the business community to do its part." Making the right decisions will not only improve public
health, it also has the potential to protect economic productivity: Employees who are sick and stay home will not spread the flu in the workplace.
"This new guidance will help our private sector partners continue to prepare for the upcoming flu season to keep our economy functioning and our critical infrastructure secure," said DHS Secretary Napolitano. "Ensuring business continuity is important to our cooperative efforts to
keep Americans safe."
There are many actions that can be taken to help reduce the spread of flu. The guidance notes the importance of using these actions, including regular and frequent hand washing and routine cleaning of commonly touched surfaces.
"One of the most important things that employers can do is to make sure their human resources and leave policies are flexible and follow public health guidance,'' said HHS Secretary Kathleen Sebelius. ``If employees are sick, they need to be encouraged to stay home. If people begin to
experience flu-like symptoms at work, they should be sent home and possibly encouraged to seek medical treatment. ''
Employers should review sick leave policies and ensure employees understand them, according to the guidance. Employers should try to make sick leave policies flexible for workers who may have to stay home with ill family members or if a child's school is closed, the CDC says.
Employers should consider offering vaccine against seasonal flu, and encourage employees to be vaccinated against seasonal and H1N1 flu, the guidance says.
Employers also might cancel non-essential face-to-face meetings and travel, and space employees farther apart, the report says. And employees who are at higher risk for flu complications might be allowed to work from home or stay home if the flu is severe, it says.
"Keeping our nation's workers safe is a top priority," said Deputy Secretary of Labor Seth Harris, who participated in the announcement. "Faced with a renewed H1N1 challenge during the coming flu season, we are developing tools that will help ensure America's workers stay
healthy and our businesses remain viable."
For more information, visit www.flu.gov.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
www.artsacrossgeorgia.com
Arts Across Georgia
Posted by
Georgia Front Page.com
at
1:33 PM
0
comments
Labels: atlanta, business, cdc, fayette front page, flu, georgia, georgia front page, government, guidelines, H1N1, leave, season, sick, symptoms
Friday, August 14, 2009
Clayton State Preparing Students and Faculty for Possible Swine Flu Outbreak
Clayton State University’s University Health Services is encouraging the Clayton State faculty and students to be prepared for flu season.
In an all-campus email communication, Dr. Julia Spinolo, director of University Health Services and assistant professor of Nursing, had a very basic message for the faculty…
“If a student has flu like symptoms (a fever of 100.5 or greater, sore throat, runny nose, and cough) please tell them to stay home!”
Spinolo also encourages faculty members to send students who appear to be ill to University Health Services (UHS) and to plan ahead.
“Develop a plan for notification of illness. Inform your students how you wish to be notified if they have the flu. Develop a contingency plan for how you will handle the continuation of instruction should you be ill and are unable to attend or conduct class for up to two weeks,” she said. “Review your attendance policies, penalties, and make up procedures for students work. Please consider that we WANT students to stay home if they are sick, so please be lenient regarding students missing class for illness.
“Consider needed changes in your syllabus and your attendance policies. Schedule make up days for tests and project/paper due dates. Consider alternative on line assignments that do not require class attendance as an option.”
Spinolo also reminds faculty about some of the basic prevention techniques, including using hand sanitizer and proper cough technique (coughing in the inner elbow instead of hands).
A similar message will be going out to the student body early next week, in conjunction with the start of fall semester classes.
A unit of the University System of Georgia, Clayton State University is an outstanding comprehensive metropolitan university located 15 miles southeast of downtown Atlanta.
---
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---
Posted by
Georgia Front Page.com
at
3:44 PM
0
comments
Labels: atlanta, brooks, county, coweta, fayette, fayette front page, fayetteville, georgia, georgia front page, H1N1, peachtree city, south metro, swine flu, tyrone, woolsey
Wednesday, August 12, 2009
Central State Hospital Taking Precautions After Confirming Case of H1N1 Virus
Central State Hospital is taking measures to prevent the spread of the H1N1 virus among its patients and staff after one consumer was confirmed to be infected with the virus Tuesday night. The consumer was taken to a local medical center where doctors there identified the virus and admitted the patient for further treatment and observation. Following long-standing protocols to deal with just such a case, Central State administrators isolated the unit at the mental hospital where the patient had been cared for and have reinforced staff training to prevent the spread of the disease.
“It’s our responsibility to provide a safe environment for clients, staff, and visitors,” said Marvin Bailey, Regional Hospital Administrator for Central State Hospital. “We have a protocol in place to address incidents like the H1N1 virus and other pandemic outbreaks. Our main focus now is making sure our staff knows what to do and is taking the necessary precautions.”
The unit of the state mental hospital where the patient was being treated houses 25 consumers. As part of the isolation protocol, those consumers are receiving treatment in the unit instead of travelling to other places on the hospital campus. They’re also eating meals there, using disposable utensils to limit the exposure of other patients and staff to the virus.
Central State Hospital (CSH) and the other six state-run behavioral health facilities have documented protocols in place to prevent the spread of infectious diseases, including pandemic influenza. Those plans are revised annually to address health concerns and new threats as they arise. CSH has provided protocol and preventive methods to all staff members as a standard precaution. The hospital has also taken additional safety measures by emphasizing proper covering when coughing and sneezing, keeping surfaces clean and reinforcing hand washing. CSH staff members are encouraged to remain at home if they show symptoms of illness.
For more information on H1N1 virus, please visit www.cdc.gov/h1n1flu/ .
--
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---
Posted by
Georgia Front Page.com
at
5:59 PM
0
comments
Labels: atlanta, brooks, county, fayette, fayette front page, fayetteville, georgia, georgia front page, H1N1, health, peachtree city, south metro, swine flu, tyrone, woolsey
Monday, August 10, 2009
Emory Begins Vaccinating Volunteers Today in First H1N1 Clinical Trial
Today Emory University researchers began vaccinating volunteer participants in the first of several planned clinical trials of a new H1N1 vaccine. The clinical trials are being conducted by the eight Vaccine and Treatment Evaluation Units (VTEUs), supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Emory began signing up several hundred interested volunteers about two weeks ago and has been screening the volunteers to make sure they fit certain criteria. Volunteers will receive their first vaccinations over the first week of the trial and will return several times over the course of nine weeks to receive additional vaccinations and blood tests.
The Emory clinical trial will evaluate the safety and immune response to an H1N1 vaccine and also help determine how the pandemic flu shot should be given along with the seasonal flu shot to make it most effective. Participants will receive two H1N1 vaccinations concurrent with, before, or after, the seasonal flu shot.
The trials are being conducted in a compressed timeframe because of the possible fall resurgence of pandemic H1N1 flu infections that may coincide with the circulation of seasonal flu strains in the Northern Hemisphere.
The trials are expected to gather critical information that will allow the NIH to quickly evaluate the new vaccines to determine whether they are safe and effective in inducing protective immune responses. The results will help determine how to begin a fall 2009 pandemic flu vaccination program.
The U. S. government declared the H1N1 outbreak a public health emergency in April and two months later, the World Health Organization classified the outbreak a pandemic, reflecting its widespread nature.
“We have had a tremendous response from volunteers wanting to participate in the clinical trials,” says Mark Mulligan, MD, principal investigator of the Emory VTEU and executive director of the Hope Clinic of the Emory Vaccine Center. “Hopefully this will make it much easier to have a vaccine available for the fall flu season. We are very appreciative of the efforts of our volunteers.”
This first adult clinical trial as well as subsequent pandemic vaccine clinical trials will be conducted at the Emory Vaccine Center’s Hope Clinic in nearby Decatur. Pediatric clinical trials will be initiated one week after the first adult trial and will be conducted at the Emory-Children’s Center on Emory University’s campus. Harry Keyserling, MD, and Paul Spearman, MD, co-directors of the Emory VTEU, lead the pediatric studies at Emory-Children’s Center.
The VTEUs were established in 1962 as a vital research component of the NIAID. The units conduct clinical trials for all infectious diseases other than HIV/AIDS. They have conducted hundreds of clinical studies over the past four decades. Emory was designated a VTEU site in 2007 and received a seven-year contract of approximately $23.7 million.
An important strength of the VTEUs is their ability to rapidly enroll large numbers of volunteers into trials and to immunize the volunteers in a safe, effective and efficient manner. This rapid-response capability is especially important for testing vaccines designed to combat pandemic influenza. Results are expected to be available weeks after the trials begin.
In addition to Emory, VTEU sites are Baylor College of Medicine, Houston; Children’s Hospital Medical Center, Cincinnati; Group Health Cooperative, Seattle; Saint Louis University, St. Louis; University of Iowa, Iowa City; University of Maryland School of Medicine, Baltimore; and Vanderbilt University, Nashville. They will be joined for these studies by Children’s Mercy Hospital in Kansas City and Duke University Medical Center.
For more information about the Emory flu clinical trials, call 877-424-HOPE (4673) for the adult and senior studies, or 404-727-4044 for the pediatric studies, or vaccine@emory.edu for further information about the upcoming trials.
---
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---
Posted by
Georgia Front Page.com
at
7:35 PM
0
comments
Labels: atlanta, brooks, county, emory, fayette, fayette front page, fayetteville, georgia, georgia front page, H1N1, peachtree city, tyrone, university, vaccine, woolsey
Wednesday, July 29, 2009
FDA Authorizes Emergency Use of Another Test for 2009 H1N1 Influenza Virus
The U.S. Food and Drug Administration has announced it has issued an Emergency Use Authorization (EUA) for a another diagnostic test for the 2009 H1N1 influenza virus, whose spread has caused the virus to be characterized as a pandemic by the World Health Organization.
The EUA for the Focus Diagnostics Influenza H1N1 (2009) Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) diagnostic test is the third diagnostic test authorized under an EUA by the FDA since the public health emergency involving the 2009 H1N1 influenza virus was declared on April 26, 2009.
The EUA allows Focus Diagnostics to distribute the test to laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. This test is not typically utilized in a doctor’s office—it is a complex laboratory test performed in an environment that has the necessary equipment. These tests are intended for use in the detection of the 2009 H1N1 influenza virus in patients with symptoms of respiratory infection.
“This authorization will contribute to the nation’s capacity for accurate testing for the 2009 H1N1 influenza virus,” said Daniel G. Schultz, M.D., director of the FDA’s Center for Devices and Radiological Health.
The Focus Diagnostics test amplifies the viral genetic material obtained from swabs of the nose or throat, or from nasal discharges. A positive result indicates that the patient is infected with the 2009 H1N1 influenza virus. However, the test does not indicate the stage of infection. A negative result does not preclude influenza virus infection.
The EUA authority allows the FDA, based on the evaluation of available data and other things, to authorize the use of unapproved medical products or unapproved uses of approved medical products following a determination and declaration of emergency. The Focus Diagnostics test is an unapproved device whose use is authorized by the EUA. The authorization ends when the declaration of emergency is terminated or when the FDA revokes the authorization.
Emergency Use Authorization is part of Project BioShield, which became law in July 2004.
-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow on Twitter: @GAFrontPage
Posted by
Georgia Front Page.com
at
12:39 PM
0
comments
Labels: atlanta, diagnostic test, emergency use authorization, fayette front page, fda, georgia, georgia front page, H1N1
Tuesday, July 28, 2009
Study Says Pregnant Women Are More Severely Impacted by Novel H1N1 Influenza Virus
Pregnant women infected with 2009 novel H1N1 had a higher rate of hospitalization and greater risk of death than the general population due to the H1N1 flu, according to a study in the Aug. 8 issue of the British medical journal Lancet.
The data collected and analyzed by the Centers for Disease Control and Prevention (CDC) are the most comprehensive available to date on the impact of this novel H1N1 flu virus among pregnant women.
"The death of a pregnant woman is always heartbreaking, and unfortunately we have been hearing reports of otherwise healthy women dying from H1N1. If a pregnant woman feels like she may have influenza, she needs to call her healthcare provider right away," said CDC’s Dr. Denise Jamieson, lead author of the study. “Clinicians who treat pregnant women should have a system in place for triaging pregnant women with influenza-like symptoms and they should not delay in initiating appropriate antiviral therapy. Some clinicians hesitate treating pregnant women with antiviral medications because of concerns for the developing fetus, but this is the wrong approach. It is critical that pregnant women, in particular, be treated promptly. "
Six deaths of pregnant women with H1N1 were reported to CDC between April 15 and June 16, 2009, representing 13 percent of the total 45 deaths reported to CDC during that time period. All were healthy prior to infection of H1N1 and subsequently developed primary viral pneumonia leading to acute respiratory distress requiring mechanical ventilation. All pregnant women who died did not receive antivirals soon enough to benefit their treatment. CDC recommends that pregnant women with suspected or confirmed influenza infection receive prompt treatment with antiviral medication.
Based on past influenza pandemics and on seasonal influenza epidemics, pregnant women have increased rates of illness and death from influenza infection.
Despite recommendations from the Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists for inactivated flu vaccine for all pregnant women, seasonal flu vaccine coverage among pregnant women is very low (less than 14 percent).
CDC has posted clinical guidance for treatment and prophylaxis of pregnant women with suspected or confirmed pandemic H1N1 2009 influenza at http://www.cdc.gov.h1n1flu/clinician_pregnant.htm.
---
Community News You Can Use
Follow us on Twitter: @gafrontpage
www.FayetteFrontPage.com
www.GeorgiaFrontPage.com
www.PoliticalPotluck.com
www.ArtsAcrossGeorgia.com
---
Posted by
Georgia Front Page.com
at
8:11 AM
0
comments
Labels: brooks, county, death, fayette, fayette front page, fayetteville, flu, georgia, georgia front page, H1N1, influenza, peachtree city, pregnant, swine flu, tyrone, vaccine, woolsey